Eton Pharmaceuticals

ETON52

$11.23arrow_drop_up4.46%$0.48

ETON52

$11.23

arrow_drop_up4.46%$0.48

Performance History

Key Stats
Open	$10.73
Prev. Close	$10.75
EPS	-0.26
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	10.55	11.34
52 Week Range	3.03	11.34

Ratios







EPS	-0.26

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Eton Pharmaceuticals (ETON)

Eton Pharmaceuticals Inc (ETON) is a pharmaceutical company specializing in the development and commercialization of innovative drug products. With a focus on creating life-changing therapies, Eton Pharmaceuticals aims to address unmet medical needs and improve patient outcomes. The company's stock price history shows a steady growth pattern, reflecting investor confidence in its robust product pipeline and strategic partnerships.

As of the latest quote, ETON stock is trading at a favorable price, offering investors an opportunity to participate in the company's promising future. Analysts suggest that Eton Pharmaceuticals Inc has strong growth potential due to its differentiated product portfolio and the increasing demand for its innovative therapies.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Sean E. Brynjelsen
Headquarters: Deer Park
Employees: 28
Exchange: NASDAQ

Keep an eye on Eton Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Eton Pharmaceuticals (ETON)?

Eton Pharmaceuticals (ETON) has a market capitalization of $290.14M. The average daily trading volume is 11.07, indicating the stock's liquidity and investor engagement.

help

What is Eton Pharmaceuticals 's (ETON) price per share?

The current price per share for Eton Pharmaceuticals (ETON) is $11.23. The stock has seen a price change of $0.48 recently, indicating a 4.47% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Eton Pharmaceuticals (ETON)?

For Eton Pharmaceuticals (ETON), the 52-week high is $11.34, which is 1.02% from the current price. The 52-week low is $3.03, the current price is 270.63% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Eton Pharmaceuticals (ETON) a growth stock?

Eton Pharmaceuticals (ETON) has shown an average price growth of -3.66% over the past three years. It has received a score of 90 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Eton Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Eton Pharmaceuticals (ETON) stock price performance year to date (YTD)?

As of the latest data, Eton Pharmaceuticals (ETON) has a year-to-date price change of 144.66%. Over the past month, the stock has experienced a price change of 38.13%. Over the last three months, the change has been 147.36%. Over the past six months, the figure is 211.94%. Looking at a longer horizon, the five-year price change stands at 79.11%.

help

Is Eton Pharmaceuticals (ETON) a profitable company?

Eton Pharmaceuticals (ETON) has a net income of -$936K, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 66.56% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -32.35% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $31.64M, with a revenue growth rate of 48.9%, providing insight into the company's sales performance and growth. The gross profit is $21.06M. Operating income is noted at -$1.19M. Furthermore, the EBITDA is -$5.31M.